Literature DB >> 9710672

Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.

D C Hooper1.   

Abstract

Topoisomerases are ubiquitous enzymes necessary for controlling the interlinking and twisting of DNA molecules. Among the four topoisomerases identified in eubacteria, two, DNA gyrase and topoisomerase IV have been exploited by nature and the pharmaceutical industry as antibacterial targets. Natural products that are inhibitors of one or both of these topoisomerases include the coumarin and cyclothialidine classes, which interfere with adenosine triphosphate hydrolysis, cinodine, flavones, and terpenoid derivatives. The plasmid-encoded bacterial peptides micron B17 and CcdB also inhibit DNA gyrase. The quinolones, a synthetic class of antibacterials that act on both DNA gyrase and topoisomerase IV have had the broadest clinical applications, however. Quinolone congeners differ in their relative potencies for DNA gyrase and topoisomerase IV Studies of an expanding set of resistant mutant enzymes and the crystal structure of the homologous enzyme in yeast have contributed to our understanding of interactions of these drugs with topoisomerase-DNA complexes and the ways in which mutations effect resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710672     DOI: 10.1086/514923

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

1.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  The Red Menace: Emerging Issues in Antimicrobial Resistance in Gram-Negative Bacilli.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

3.  High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.

Authors:  A Mazzariol; Y Tokue; T M Kanegawa; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

4.  In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites.

Authors:  D B Zamble; D A Miller; J G Heddle; A Maxwell; C T Walsh; F Hollfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

Review 5.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Alteration of Escherichia coli topoisomerase IV to novobiocin resistance.

Authors:  Christine D Hardy; Nicholas R Cozzarelli
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

7.  Development and evaluation of a novel single-nucleotide-polymorphism real-time PCR assay for rapid detection of fluoroquinolone-resistant Mycoplasma bovis.

Authors:  M Ben Shabat; I Mikula; I Gerchman; I Lysnyansky
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

8.  DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones.

Authors:  C M Bébéar; H Renaudin; A Charron; M Clerc; S Pereyre; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  Disentangling DNA during replication: a tale of two strands.

Authors:  Christine D Hardy; Nancy J Crisona; Michael D Stone; Nicholas R Cozzarelli
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-01-29       Impact factor: 6.237

10.  Design and development of topoisomerase inhibitors using molecular modelling studies.

Authors:  Muthu K Kathiravan; Madhavi M Khilare; Aparna S Chothe; Madhuri A Nagras
Journal:  J Chem Biol       Date:  2012-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.